Immune checkpoint inhibitors (ICIs) targeting program-cell death 1 or its ligand (anti-PD1/anti-PDL1) and cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) have revolutionized the treatment paradigm for multiple cancers and have brought unprecedented deep and durable treatment efficacy to patients with metastatic disease [1,2,3,4,5]. Here, CTLA4 is linked to metastatic neoplasm.